Expanded Canadian approval for Qiagen's HPV test
This article was originally published in Clinica
The digene human papillomavirus (HPV) test platform developed by Qiagen may now be used in Canada to screen women for cervical cancer, with or without the Pap smear test. The digene HC2 High-Risk HPV DNA test was previously approved in Canada for co-testing with the Pap test; this label update now enables primary, front-line HPV screening. Health Canada has also approved updated labelling for the Venlo, Netherlands-based firm's HPV test, expanding approval to cover screening BD SurePath specimens. Testing with Qiagen's digene HPV Test can now be performed in labs on three different specimen collection vials: BD SurePath, Hologic PreservCty and Qiagen's digene Specimen Transport Medium.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.